Filing Flows › BridgeBio Pharma (BBIO) › Q3 2026 › vs Q2 2026
BridgeBio Pharma (BBIO) Q3 2026 vs Q2 2026 (quarter over quarter)
BridgeBio Pharma's revenue rose $109M (+45%) from $244M in Q2 2026 to $353M in Q3 2026. The biggest changes: License and services revenue +$73.5M (14×); Net product revenue +$30.9M (+14%); Royalty revenue +$5.1M (+33%).
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Net product revenue | $253M | $222M | $30.9M | +14% |
| License and services revenue | $79.3M | $5.8M | $73.5M | 14× |
| Royalty revenue | $20.5M | $15.4M | $5.1M | +33% |
| Revenue | $353M | $244M | $109M | +45% |
| Net loss | $60.5M | $156M | −$95.4M | -61% |
| Costs & expenses | $414M | $400M | $14.1M | +4% |
| Operating costs | $365M | $351M | $14.1M | +4% |
| Interest & other, net | $47.6M | $48.8M | −$1.2M | -2% |
| Income tax | $1.2M | $0 | $1.2M | — |
| Cost of revenue | $20.4M | $15.0M | $5.4M | +36% |
| Research & development | $144M | $149M | −$5.9M | -4% |
| SG&A | $201M | $186M | $14.6M | +8% |
| Operating cash sources | $85.1M | $116M | −$31.1M | -27% |
| Depreciation & amortization | $1.1M | $1.1M | $16K | +2% |
| Share-based compensation | $39.9M | $44.1M | −$4.2M | -10% |
| Cash used in operations | $44.2M | $71.1M | −$26.9M | -38% |
| Net loss absorbed | $60.5M | $156M | −$95.4M | -61% |
| Working capital & other | $24.6M | −$39.7M | $64.3M | — |
Questions
How much did BridgeBio Pharma's revenue grow quarter over quarter in Q3 2026?
BridgeBio Pharma's revenue rose $109M (+45%) from $244M in Q2 2026 to $353M in Q3 2026.
What drove BridgeBio Pharma's revenue change in Q3 2026?
License and services revenue +$73.5M (14×); Net product revenue +$30.9M (+14%); Royalty revenue +$5.1M (+33%).